Revolutionary Treatment for Type 1 Diabetes
The National Health Service (NHS) in England and Wales has announced the availability of Teplizumab, the first drug capable of delaying the onset of type 1 diabetes. This immunotherapy treatment could provide individuals with an additional three years before symptoms appear and the need for lifelong insulin therapy begins.
Impact and Eligibility
Health officials have described this development as "genuinely exciting," anticipating that hundreds of children and young people will benefit annually. Type 1 diabetes can manifest at any age, but it is most frequently diagnosed during early adolescence. Patient advocacy groups have lauded the drug's introduction as "momentous," recognizing the culmination of decades of research and effort.
"If it were your child or someone you love, you would want to do everything possible to give them more years without the daily burden of managing this relentless condition," stated Karen Addington, chief executive of Breakthrough T1D. "We now have a treatment that can help make that possible."
Understanding Type 1 Diabetes
Unlike type 2 diabetes, which is often linked to weight, type 1 diabetes occurs when the body's immune system mistakenly attacks and destroys the insulin-producing cells in the pancreas. Individuals with type 1 diabetes must regularly monitor their blood glucose levels and administer insulin, either via injections or a pump, to compensate for their body's inability to produce sufficient amounts of the hormone.
Patient Experiences
Theo Sebastian-Jenkins, diagnosed at age four, experienced symptoms like extreme fatigue, constant thirst, and weight loss. While he was too young to qualify for Teplizumab, which is approved for individuals aged eight and older, his parents emphasize the profound impact a delay in diagnosis could have. Managing his condition involves meticulous dietary control and constant blood sugar monitoring to prevent both dangerously low (hypoglycemia) and persistently high (hyperglycemia) levels, which can lead to long-term complications.
Dima Boichak, from Newbury, was nine when a research study revealed his high risk of developing type 1 diabetes. He was among the first to receive Teplizumab on compassionate grounds. His mother, Elena, described the 14-day intravenous infusion process as challenging but ultimately worthwhile, hoping it grants her son extra years of a normal childhood before requiring insulin.
Treatment Logistics and Future Outlook
Teplizumab is administered as an infusion before symptoms manifest, requiring a prior blood test to confirm the immune system has begun attacking the pancreas. While Italy has a national screening program for children and young people, routine testing for type 1 diabetes is not yet standard on the NHS in the UK, although charities are advocating for its implementation. Most diagnoses occur without a close family history, suggesting environmental factors may also play a role.
The National Institute for Health and Care Excellence (NICE) has recommended the drug for use in England and Wales. NICE estimates that approximately 1,100 adults and children could be eligible in the first year, with around 820 per year in the long term. While the published price for a course of treatment is around £150,000, the NHS has negotiated a confidential discount with the manufacturer, Sanofi.
Breakthrough T1D, which supported early research for Teplizumab, notes that several other immunotherapy treatments for type 1 diabetes are currently in development. The long-term vision is for new patients to receive personalized combinations of these drugs, potentially eliminating the need for insulin therapy entirely.
NICE guidance does not automatically apply in Northern Ireland, and Scotland's Scottish Medicines Consortium is expected to issue its advice on Teplizumab in early 2027.
Source: First drug to delay onset of type 1 diabetes made available on NHS